Sentinel node biopsy in breast cancer: Five years experience from Denmark

Christiansen, Peer; Friis, Esbern; Balslev, Eva; Jensen, Disa; Møller, Susanne

doi:10.1080/02841860802023206

Cited by 35 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The requirement for the number of retrieved axillary lymph nodes became strengthened during the period from at least one node in 1977 to at least 4 but preferably 10 nodes in 1990 and by 1994 DBCG stated that at least 10 removed lymph nodes should be the national standard of level I-II dissection of the axilla [1]. The sentinel node technique was introduced as an experimental procedure in 1998 and nationwide from 2002 [8]. Since then axillary dissection was limited to cases non-eligible for this technique and to sentinel node positive cases.…”

Section: Methodsmentioning

confidence: 99%

“…We therefore analysed OS according to nodal status (node negative (0), 1Á3 positive nodes, and 4' positive nodes) for the whole series ( Figure 5, upper panel) of patients and for those with at least 10 examined nodes, or sentinel node technique applied ( Figure 5, lower panel). After the introduction of the sentinel node technique 10 examined nodes was required only if the tumour was node positive, or if the inclusion criteria for the sentinel node method [8] was not fulfilled. As appears, nodal status is a strong prognostic factor and there is a significantly inferior prognosis with increasing number of positive nodes.…”

Section: Nodal Statusmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry

et al. 2008

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Nodal Statusmentioning

confidence: 99%

Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry

et al. 2008

Self Cite

View full text Add to dashboard Cite

“…In that period, metastases were classified according to the American Joint Committee on Cancer (AJCC) staging manual [8] in combination with cell count, where metastases between 10 and 100 tumor cells were defined as micrometastases and less than 10 cells were defined as ITC [9]. Information on age at diagnosis, tumor size, histology type, malignancy grade, hormone receptor status, HER2 status, number of removed sentinel nodes, number of positive sentinel nodes, lymphovascular invasion, location of tumor in the breast and presence of non-sentinel node metastases have been retrieved from the DBCG database.…”

Section: Methodsmentioning

confidence: 99%

Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers

et al. 2015

Self Cite

View full text Add to dashboard Cite

(182) in the sentinel node. Patients were cross-checked in the Danish Quality Database of Mammography Screening and 481 patients were identified as screen-detected cancers. The remaining 474 patients were considered as having symptomatic cancers. Multivariate analyses of the risk of non-sentinel node metastases were performed including known risk factors for non-sentinel node metastases as well as method of detection. Results: 18% of the patients had metastases in non-sentinel nodes. This was evenly distributed between patients with symptomatic and screen-detected cancers; 18.5% vs 17.5% (OR 1.07; 95% CI 0.77-1.49; p ¼ 0.69). In patients with micrometastases 21% had non-sentinel node metastases in the group with symptomatic cancers compared to 19% of patients with screen-detected cancers. This difference was not significant (OR 1.16; 95% CI 0.81-1.65, p ¼ 0.43). Neither the multivariate analysis showed an increased risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected cancers (OR 1.12, CI 0.77-1.62, p ¼ 0.55). In patients with ITCs 8% of patients with symptomatic cancers had non-sentinel node metastases compared to 13% of patients with screen-detected cancers. This difference was not significant (OR 0.58; 95% CI 0.22-1.54, p ¼ 0.27). In the multivariate analysis, the risk of non-sentinel node metastases was still not significantly increased in patients with symptomatic cancers compared to screen-detected cancers (OR 0.45; 95% CI 0.16-1.27, p ¼ 0.13). Conclusion: We did not find any clinically relevant difference in the risk of non-sentinel node metastases between patients with symptomatic and screen-detected cancers with micrometastases or ITC in the sentinel node.

show abstract

“…The rate of axillary recurrence after negative SLNB based on 8 different studies with a mean duration follow up of 34.9 months was 0.51% (32)(33)(34)(35)(36)(37)(38)(39). The society-based study of Poletti et al at general hospitals showed that SLNB is a reliable and risk-free method in cases of early breast cancer (34).…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 99%

Axillary Recurrence Rate in Patients with Breast Cancer and Negative Sentinel Lymph Node Biopsy

et al. 2017

View full text Add to dashboard Cite

Background: Sentinel lymph node biopsy is the standard method of evaluating and staging the axilla in the patients with early stage of the breast cancer. The aim of this study is to evaluate the axillary recurrence rate in patients with negative sentinel node biopsy. Methods: From 2006 to 2010, all the patients with a negative sentinel lymph node in their pathologic results were introduced in the study. All patients were invited to the breast cancer clinic for the follow up examination. The axillary ultrasonography was performed to determine the recurrence. Results: Among 150 female patients with negative sentinel lymph node, 52 were entered into the study and were followed up. The

show abstract

Sentinel node biopsy in breast cancer: Five years experience from Denmark

Cited by 35 publications

References 12 publications

Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry

Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry

Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers

Axillary Recurrence Rate in Patients with Breast Cancer and Negative Sentinel Lymph Node Biopsy

Contact Info

Product

Resources

About